"The global regenerative medicine markets comprises of many key market players competing for markets shares like Novartis AG ...
DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual ...
Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...
Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...
Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The ...
In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual ...
Gilead Sciences (GILD) closed the latest trading day at $87.23, indicating a -1.05% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.92%. Meanwhile ...
In conclusion, Eli Lilly, Gilead Sciences, and Amgen stand out as compelling choices for investors seeking a blend of growth and dividends in the healthcare sector. Each company showcases strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback